Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)

PHASE2CompletedINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

July 25, 2022

Study Completion Date

July 25, 2022

Conditions
Cannabis Use Disorder
Interventions
DRUG

PF 04457845

Study medication will be administered at 4mg by mouth daily for eight weeks.

DRUG

Placebo Oral Tablet

Placebo comparator will be administered by mouth daily for eight weeks.

Trial Locations (4)

10032

Columbia University Medical College / New York State Psychiatric Institute, New York

21224

Johns Hopkins University, Baltimore

29425

Medical University of South Carolina, Charleston

06519

Connecticut Mental Health Center, New Haven

All Listed Sponsors
collaborator

Columbia University

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

Medical University of South Carolina

OTHER

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER

NCT03386487 - Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) | Biotech Hunter | Biotech Hunter